Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes
Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes
About this item
Full title
Author / Creator
Publisher
Boston: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Boston: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
To the Editor:
Preventive strategies for cardiovascular complications in type 2 diabetes mellitus are essential. Subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonists have significantly reduced cardiovascular risk in four of six published outcome trials.
1,2
In the Peptide Innovation for Early Diabetes Treatment (PIONEER) 6 trial...
Alternative Titles
Full title
Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2316780740
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2316780740
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMc1913157
